Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANAMYCIN SULFATE vs BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of m RNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Short-term treatment of serious infections caused by susceptible strains of bacteria (e.g., Escherichia coli, Proteus species, Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species),Adjunctive therapy in staphylococcal infections,Mycobacterium tuberculosis infections (as second-line agent)
Treatment of superficial ocular infections caused by susceptible organisms,Reduction of inflammation in corticosteroid-responsive ocular conditions,Off-label: treatment of otitis externa (otic preparations)
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (Cr Cl <10 m L/min).
Bacitracin: 1.5 h (systemic) but clinically irrelevant as topical. Neomycin: 2-3 h (systemic). Polymyxin B: 4.5-6 h (systemic). Hydrocortisone acetate: 1.5-2.5 h (plasma); clinical effect outlasts serum half-life due to intracellular activity.
Not metabolized; excreted unchanged by glomerular filtration.
Bacitracin: not metabolized, excreted renally; neomycin: minimally metabolized, excreted renally; polymyxin B: metabolism unknown, excreted renally; hydrocortisone acetate: hepatic metabolism via CYP3A4, glucuronidation, sulfation.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Bacitracin: renal (minimal systemic absorption; eliminated unchanged in urine if absorbed). Neomycin: renal (90-95% excreted unchanged in urine after systemic absorption). Polymyxin B: renal (60% excreted unchanged over 24h; prolonged elimination in renal impairment). Hydrocortisone acetate: hepatic metabolism (glucuronidation, sulfation) and renal excretion of metabolites.
Low; approximately 0-10%, primarily to albumin.
Bacitracin: ~10% (albumin). Neomycin: <30% (albumin). Polymyxin B: 55-60% (albumin, alpha-1-acid glycoprotein). Hydrocortisone acetate: 90-95% (corticosteroid-binding globulin, albumin).
0.2-0.4 L/kg; reflects distribution primarily into extracellular fluid.
Bacitracin: 0.3 L/kg (minimal distribution). Neomycin: 0.2-0.4 L/kg (extracellular fluid). Polymyxin B: 0.6-0.8 L/kg (extensively bound to cell membranes). Hydrocortisone acetate: 0.3-0.6 L/kg (total body water).
Intramuscular: ~100%; Oral: <1% (not absorbed); Ophthalmic: minimal systemic absorption (<1%).
Topical/otic/ophthalmic: negligible systemic absorption (<1% for bacitracin, neomycin, polymyxin B; <5% for hydrocortisone acetate). Oral: not applicable (not administered systemically).
GFR 50-90 m L/min: administer every 24 hours. GFR 10-50 m L/min: administer every 24-72 hours. GFR <10 m L/min: administer every 72-96 hours. Dose adjustments based on serum concentrations.
No systemic absorption anticipated with topical, ophthalmic, or otic use; however, for extensive topical application, caution in renal impairment due to neomycin and polymyxin B. GFR <30 m L/min: monitor for nephrotoxicity; reduce frequency if topical use over large areas.
No dose adjustment required for hepatic impairment. Kanamycin is primarily renally eliminated.
No specific adjustment required for topical, ophthalmic, or otic use. Hydrocortisone acetate is hepatically metabolized; however, systemic exposure is minimal. Child-Pugh Class C: use with caution if applied to large areas or broken skin.
Neonates: 7.5-10 mg/kg IV every 12 hours. Infants and children: 15 mg/kg/day IM or IV divided every 8-12 hours. Maximum total daily dose: 1.5 g.
Children: Apply a thin layer to affected area 3-4 times daily. Ophthalmic: Use same as adult dose. Otic: Infants and children: 3 drops into affected ear(s) 3-4 times daily. Safety and efficacy in neonates not established.
Lower initial and maintenance doses due to age-related decrease in renal function. Monitor renal function and serum concentrations closely. Consider dosing based on ideal body weight and renal function.
No specific dose adjustment required. Use with caution in elderly with impaired renal or hepatic function, especially if applied to large areas. Monitor for skin atrophy and systemic effects of hydrocortisone with prolonged use.
Boxed warnings: Neurotoxicity (ototoxicity vestibular and auditory), nephrotoxicity, and neuromuscular blockade. Risk increases with high doses, prolonged use, renal impairment, and concurrent use of other ototoxic/nephrotoxic drugs. Monitor renal function and drug levels. Avoid in pregnancy.
None.
Ototoxicity (vestibular and auditory) can be irreversible, especially with renal impairment, high doses, prolonged therapy, or concurrent ototoxic drugs. Nephrotoxicity risk; monitor renal function and serum drug levels. Neuromuscular blockade risk, especially with anesthetics, neuromuscular blocking agents, or in patients with neuromuscular disorders. Superinfection, Clostridium difficile diarrhea. Use caution in elderly, dehydration, and pre-existing renal impairment.
Prolonged use may lead to secondary infections (e.g., fungal) or hypersensitivity; ophthalmic use may cause increased intraocular pressure, cataract formation, and delayed wound healing; avoid use in patients with epithelial herpes simplex keratitis; systemic absorption may cause nephrotoxicity and ototoxicity (especially neomycin); use with caution in hepatic impairment.
Hypersensitivity to kanamycin or other aminoglycosides; myasthenia gravis (increased risk of neuromuscular blockade).
Hypersensitivity to any component; ocular tuberculosis, viral infections of the cornea (e.g., herpes simplex keratitis), fungal diseases of the eye; untreated purulent infections; use in ears with tympanic membrane perforation (otic preparations).
No significant food interactions known. Kanamycin absorption is not affected by food. However, maintain adequate hydration.
No significant food interactions. No dietary restrictions required.
First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible bilateral hearing loss) and nephrotoxicity, especially with prolonged or high-dose therapy.
Teratogenic risk is minimal due to negligible systemic absorption from topical application. No studies report fetal harm from bacitracin, neomycin, polymyxin B, or hydrocortisone acetate when used topically. Avoid prolonged use of high-dose hydrocortisone during first trimester due to potential corticosteroid effects.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution in breastfeeding due to potential for infant ototoxicity and nephrotoxicity; monitor infant for diarrhea, rash, and hearing loss.
Systemic absorption is minimal; topical application likely poses low risk to nursing infant. M/P ratio not established for the combination. Avoid application to breast area to prevent infant ingestion.
No standard dosing adjustment required for pregnancy; however, increased volume of distribution may require higher loading doses. Tight therapeutic drug monitoring indicated due to altered renal clearance.
No dose adjustment required for topical application during pregnancy. Use sparingly on limited areas to minimize systemic absorption.
Kanamycin is an aminoglycoside antibiotic used primarily for serious Gram-negative infections. Monitor peak and trough levels to avoid ototoxicity and nephrotoxicity; typical therapeutic peaks: 15-30 mcg/m L, troughs <5 mcg/m L. Avoid concurrent use with other nephrotoxic or ototoxic drugs (e.g., furosemide, vancomycin, cisplatin). Adjust dose in renal impairment using creatinine clearance. Intramuscular administration preferred; avoid rapid IV push. Use with caution in myasthenia gravis or Parkinson's disease due to neuromuscular blockade potential.
This combination product is used for otitis externa and certain ophthalmic infections. The hydrocortisone reduces inflammation, but can mask signs of fungal or viral superinfection. Avoid use in patients with tympanic membrane perforation due to risk of ototoxicity from neomycin and polymyxin B. Neomycin carries sensitization risk; prolonged use may cause contact dermatitis. Monitor for overgrowth of non-susceptible organisms when used beyond 10 days.
Complete the entire course of therapy even if you feel better.,Report any hearing loss, tinnitus, dizziness, or changes in urination immediately.,Stay well hydrated unless instructed otherwise.,Avoid taking other medications without consulting your doctor, especially diuretics or other antibiotics.,This medication may cause nausea; take with food if tolerated.
Use exactly as prescribed; do not exceed recommended duration.,Avoid contact with eyes unless specifically directed for ophthalmic use.,Do not use if you have a perforated eardrum or ear discharge.,Stop use and notify your doctor if symptoms worsen or persist after 10 days.,Inform your doctor if you experience new pain, redness, or swelling.,Keep this medication out of reach of children.
"Kanamycin, an aminoglycoside antibiotic, may reduce the renal clearance of Lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID), by competitively inhibiting tubular secretion or altering renal perfusion. This interaction can lead to elevated serum levels of Lornoxicam, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may present with worsening renal function or NSAID-related side effects, especially in those with pre-existing renal compromise or dehydration."
"Kanamycin, an aminoglycoside antibiotic, increases the nephrotoxic potential of Cisplatin, a platinum-based chemotherapeutic agent, through additive damage to the proximal renal tubules. This synergistic effect elevates the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or those receiving other nephrotoxic drugs. Clinically, this interaction may lead to reduced renal function, electrolyte imbalances, and delayed elimination of both agents, potentially exacerbating systemic toxicity."
"The coadministration of Kanamycin and Vancomycin results in synergistic nephrotoxicity due to additive insult to the proximal renal tubules. Both aminoglycoside and glycopeptide antibiotics accumulate in the renal cortex, causing tubular cell necrosis and acute kidney injury (AKI). This interaction significantly increases the risk of renal impairment, potentially leading to irreversible kidney damage, particularly in patients with pre-existing renal compromise, advanced age, or prolonged therapy."
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANAMYCIN SULFATE vs BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, answered by our medical review team.
KANAMYCIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.. BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is a Aminoglycoside Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of m RNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANAMYCIN SULFATE and BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANAMYCIN SULFATE is: 15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.. The standard adult dose of BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is: Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining KANAMYCIN SULFATE and BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE. Bacitracin may increase the nephrotoxic activities of Kanamycin. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. KANAMYCIN SULFATE is classified as Category C. First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible. BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE is classified as Category A/B. Teratogenic risk is minimal due to negligible systemic absorption from topical application. No studies report fetal harm from bacitracin, neomycin, polymyxin B, or hydrocortisone a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.